Document:

Voting and Lock-Up Agreement

 Exhibit 10.4 
 VOTING AND LOCK-UP AGREEMENT 
 This VOTING AND LOCK-UP AGREEMENT (this “Agreement”) dated as of
October 16, 2006 among PRIME BIOSOLUTIONS, LLC, a Delaware limited liability company (the ”Company”), EMERGE INTERACTIVE, INC., a Delaware corporation (“eMerge”) and THE BIEGERT FAMILY IRREVOCABLE
TRUST, as a stockholder of eMerge (the ”Stockholder”). 
 RECITALS 
 The Stockholder “beneficially owns” (as such term is defined in Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) and is
entitled to dispose of (or to direct the disposition of) and to vote (or to direct the voting of) the number of shares of Common Stock, $0.01 par value per share, of eMerge (the ”Stock”) set forth opposite the Stockholder’s name
on Schedule A hereto (such shares of Stock, together with all other shares of capital stock of the Company acquired by the Stockholder after the date hereof and during the term of this Agreement, being collectively referred to herein as
the “Subject Shares”). 
 Concurrently with the execution and delivery of this Agreement, eMerge Merger Sub, LLC., a Delaware limited
liability company which is wholly owned by eMerge (“Merger Sub”), eMerge, the Company and Prime Bioshield, LLC, a Nebraska limited liability company which is the sole owner of the Company (“Shield”) are entering into an
Agreement and Plan of Merger (the “Merger Agreement”) providing for the merger of the Company with and into Merger Sub, with Merger Sub surviving the Merger (the “Merger”) upon the terms and subject to the conditions set forth
therein. 
 As a condition to entering into the Merger Agreement, the Company and Shield required that the Stockholder enter into this Agreement, and the
Stockholder desires to enter into this Agreement to induce the Company and Shield to enter into the Merger Agreement. 
 The Board of Directors of eMerge has
taken all actions so that the restrictions contained in the Company’s certificate of incorporation and the Delaware General Corporation Law (the ”DGCL”) applicable to a “business combination” will not apply to the
execution, delivery or performance of this Agreement or the Merger Agreement, or to the consummation of the Merger, this Agreement and the Merger Agreement. 
 NOW, THEREFORE, in consideration of the foregoing and the mutual premises, representations, warranties, covenants and agreements contained herein, the parties hereto, intending to be legally bound, hereby agree as follows: 
  

 1 

	1.	Representations and Warranties of the Stockholder. 

 The Stockholder represents and warrants to the other parties hereto as follows: 
 (a)
Authority. The Stockholder is duly organized, validly existing and in good standing under the laws of its jurisdiction of incorporation or organization (as applicable). Such Stockholder has all requisite legal power (corporate or
other) and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered by such Stockholder and constitutes a valid and binding obligation of
such Stockholder enforceable in accordance with its terms subject to (i) bankruptcy, insolvency, moratorium and other similar laws now or hereafter in effect relating to or affecting creditors’ rights generally, and (ii) general
principles of equity (regardless of whether considered in a proceeding at law or in equity). If such Stockholder is a trust, no consent of any beneficiary is required for the execution and delivery of this Agreement or the consummation of the
transactions contemplated hereby. 
 (b) No Conflicts. (i) No filing by such Stockholder with any
governmental body or authority, and no authorization, consent or approval of any other person is necessary for the execution of this Agreement by such Stockholder and the consummation by such Stockholder of the transactions contemplated hereby and
(ii) none of the execution and delivery of this Agreement by such Stockholder, the consummation by such Stockholder of the transactions contemplated hereby or compliance by such Stockholder with any of the provisions hereof shall
(A) conflict with or result in any breach of the organizational documents of such Stockholder, (B) result in, or give rise to, a violation or breach of or a default under (with or without notice or lapse of time, or both) any of the terms
of any material contract, trust agreement, loan or credit agreement, note, bond, mortgage, indenture, lease, permit, understanding, agreement or other instrument or obligation to which such Stockholder is a party or by which such Stockholder or any
of its Subject Shares or assets may be bound, or (C) violate any applicable order, writ, injunction, decree, judgment, statute, rule or regulation, except for any of the foregoing as would not reasonably be expected to prevent such Stockholder
from performing its obligations under this Agreement. 
 (c) The Subject Shares. Schedule A sets
forth, opposite the Stockholder’s name, the number of Subject Shares over which such Stockholder has record or beneficial ownership as of the date hereof. As of the date hereof, the Stockholder is the record or beneficial owner of the Subject
Shares denoted as being owned by such Stockholder on Schedule A (or is trustee of a trust that is the record holder of and whose beneficiaries are the beneficial owners of such Subject Shares) and has the sole power to vote (or cause to
be voted) such Subject Shares. Except as set forth on such Schedule A, neither such Stockholder nor any controlled affiliate of a Stockholder owns or holds any right to acquire any additional shares of any class of capital stock of the
Company or other securities of the Company or any interest therein or any voting rights with respect to any securities of the Company. Such Stockholder has good and valid title to the Subject Shares denoted as being owned by such Stockholder on
Schedule A, free and clear of any and all pledges, mortgages, liens, charges, proxies, voting agreements, encumbrances, 

  

 2 

 
adverse claims, options, security interests and demands of any nature or kind whatsoever, other than those created by this Agreement, as disclosed on
Schedule A, or as would not prevent such Stockholder from performing its obligations under this Agreement. 
 (d)
Reliance By the Company and Shield. The Stockholder understands and acknowledges that the Company and Shield are entering into the Merger Agreement in reliance upon such Stockholder’s execution and delivery of this Agreement.

 (e) Litigation. As of the date hereof, there is no action, proceeding or investigation pending or threatened
against such Stockholder that questions the validity of this Agreement or any action taken or to be taken by such Stockholder in connection with this Agreement. 
  

	2.	Representations and Warranties of the Company and Shield. 

 The Company hereby represents and warrants to the Stockholder as follows: 
 (a) Due
Organization, etc. The Company is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization. The Company has all requisite limited liability power and authority to execute and deliver this
Agreement and to consummate the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered by the Company and constitutes a valid and binding obligation of the Company, enforceable in accordance with its terms
subject to (i) bankruptcy, insolvency, moratorium and other similar laws now or hereafter in effect relating to or affecting creditors’ rights generally, and (ii) general principles of equity (regardless of whether considered in a
proceeding at law or in equity). 
 (b) Conflicts. (i) No filing by the Company with any governmental body
or authority, and no authorization, consent or approval of any other person is necessary for the execution of this Agreement by the Company, and the consummation by the Company of the transactions contemplated hereby and (ii) none of the
execution and delivery of this Agreement by the Company, the consummation by the Company of the transactions contemplated hereby or compliance by the Company with any of the provisions hereof shall (A) conflict with or result in
any breach of the organizational documents of the Company, (B) result in, or give rise to, a violation or breach of or a default under (with or without notice or lapse of time, or both) any of the terms of any material contract, loan or
credit agreement, note, bond, mortgage, indenture, lease, permit, understanding, agreement or other instrument or obligation to which the Company is a party or by which the Company or any of its assets may be bound, or (C) violate any
applicable order, writ, injunction, decree, judgment, statute, rule or regulation, except for any of the foregoing as would not prevent the Company from performing its obligations under this Agreement. 
  

 3 

	3.	Covenants of the Stockholder. 

 Until the termination of this
Agreement in accordance with Section 5, the Stockholder, in its capacity as such, agrees as follows: 
 (a) At any
meeting of the stockholders of eMerge (“eMerger Meeting”) or at any adjournment, postponement or continuation thereof or in any other circumstances occurring prior to the eMerge Meeting upon which a vote, consent or other approval
(including by written consent) with respect to the Merger and the Merger Agreement is sought , the Stockholder shall vote (or cause to be voted) the Subject Shares (and each class thereof) (i) in favor of the approval of each matter recommended
by the Board of Directors of eMerge to be undertaken in connection with the Merger, including, if required, the approval and adoption of the Merger Agreement and the transactions contemplated hereby and any matter that could reasonably be expected
to facilitate the Merger; (ii) in favor of any alternative structure as may be agreed upon by the Company, Shield, Merger Sub and eMerge to reflect the acquisition by Shield of control of eMerge, provided that such alternative structure is on
terms in the aggregate no less favorable to the Stockholder than the terms of the Merger Agreement; and (iii) except with the written consent of the Company, against any Takeover Proposal, the consummation of any Superior Proposal or any
action, proposal, or agreement or transaction (other than the Merger, the Merger Agreement or the transaction contemplated thereby) that would result in a breach of any covenant, representation or warranty or any other obligation or agreement of
eMerge under the Merger Agreement which could result in any of the conditions to eMerge’s obligations under the Merger Agreement not being fulfilled or which could be inconsistent with the Merger or any other transaction contemplated by the
Merger Agreement. Any such vote shall be cast or consent shall be given in accordance with such procedures relating thereto so as to ensure that it is duly counted for purposes of determining that a quorum is present and for purposes of recording
the results of such vote or consent. Such Stockholder agrees not to enter into any agreement or commitment with any person the effect of which would be inconsistent with or violative of the provisions and agreements contained in this
Section 3(a). This Agreement is intended to bind the Stockholder as a stockholder of eMerge only with respect to the specific matters set forth herein. 
 (b) Such Stockholder agrees not to, directly or indirectly, (i) sell, transfer, tender, pledge, encumber, assign or otherwise dispose
of (collectively, a “Transfer”) or enter into any agreement, option or other arrangement with respect to, or consent to a Transfer of, or convert or agree to convert, any or all of the Subject Shares to any person, other than in accordance
with the Merger Agreement, or (ii) grant any proxies (other than eMerge proxy card in connection with the eMerge Meeting if and to the extent such proxy is consistent with the Stockholder’s obligations under Section 3(a) hereof),
deposit any Subject Shares into any voting trust or enter into any voting arrangement, whether by proxy, voting agreement or otherwise, with respect to any of the Subject Shares, other than pursuant to this Agreement. Such Stockholder further agrees
not to commit or agree to take any of the foregoing actions or take any action that would have the effect of preventing, impeding, interfering with or adversely affecting its ability to perform its obligations under this Agreement. 
  

 4 

 (c) The Stockholder shall not, nor shall such Stockholder permit any controlled affiliate
of such Stockholder to, nor shall such Stockholder act in concert with or permit any controlled affiliate to act in concert with any person to make, or in any manner participate in, directly or indirectly, a “solicitation” (as such term is
used in the rules of the Securities and Exchange Commission (“SEC”)) of proxies or powers of attorney or similar rights to vote, or seek to advise or influence any person with respect to the voting of, any shares of Stock intended to
facilitate any Takeover Proposal or to cause stockholders of eMerge not to vote to approve and adopt the matters recommended by the eMerge Board of Directors in connection with the Merger. Such Stockholder shall not, and shall direct any investment
banker, attorney, agent or other adviser or representative of such Stockholder not to, directly or indirectly, through any officer, director, agent or otherwise, enter into, solicit, initiate, conduct or continue any discussions or negotiations
with, or knowingly encourage or respond to any inquiries or proposals by, or provide any information to, any person, other the Company, relating to any Takeover Proposal. Such Stockholder hereby represents that, as of the date hereof, it is not
engaged in discussions or negotiations with any party other than the Company with respect to any Takeover Proposal. 
 (d) The
Stockholder agrees that any shares of Stock of eMerge that the Stockholder purchases or with respect to which the Stockholder otherwise acquires beneficial ownership after the date of this Agreement and prior to the Termination Date (“New
Shares”), and any and all other shares or securities of eMerge issued, exchanged, issuable or exchangeable in respect of New Shares shall be subject to the terms and conditions of this Agreement to the same extent as if they constituted shares
of Stock. 
  

	4.	Stockholder Capacity. 

 No Person executing this Agreement
who is or becomes during the term of this Agreement a director or officer of eMerge shall be deemed to make any agreement or understanding in this Agreement in such Person’s capacity as a director or officer. The Stockholder is entering into
this Agreement solely in its capacity as the record holder or beneficial owner of, or the trustee of a trust whose beneficiaries are the beneficial owners of, such Stockholder’s Subject Shares. 
  

	5.	Termination. 

 This Agreement shall terminate (i) upon
the earlier of (A) the Effective Time of the Merger, and (B) the termination of the Merger Agreement, or (ii) at any time upon notice by the Company to the Stockholders, provided that in the event of a change to the terms of the
Merger Agreement that is materially adverse to the Stockholder, the Stockholder shall have the right to terminate this Agreement (the date of any such termination shall be referred to herein as the ”Termination Date”). No party hereto
shall be relieved from any liability for intentional breach of this Agreement by reason of any such termination. Notwithstanding the foregoing, Sections 6, 8 and 9 and Sections 11 through 21, inclusive, of this Agreement shall survive the
termination of this Agreement. 
  

 5 

	6.	Appraisal Rights. 

 To the extent permitted by applicable
law, the Stockholder hereby waives any rights of appraisal or rights to dissent from the Merger that it may have under applicable law. 
  

	7.	Publication. 

 Such Stockholder hereby authorizes eMerge and
the Company to publish and disclose in the Proxy Statement (including any and all documents and schedules filed with the SEC relating thereto) such Stockholder’s identity and ownership of shares of Stock of eMerge and the nature of its
commitments, arrangements and understandings pursuant to this Agreement. 
  

	8.	Governing Law. 

 This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware, without regard to any principles or rules of conflicts of laws thereof. 
  

	9.	Jurisdiction; Waiver of Jury Trial. 

 (a) Each of the parties hereto irrevocably and unconditionally (i) agrees that any legal suit, action or proceeding brought by any party hereto arising out of or based upon this Agreement or the transactions contemplated hereby may be
brought in the courts of the State of Delaware or the United States District Court for the District of Delaware (each, a “Delaware Court”), (ii) waives, to the fullest extent it may effectively do so, any objection which it may
now or hereafter have to the laying of venue of any such proceeding brought in any Delaware Court, and any claim that any such action or proceeding brought in any Delaware Court has been brought in an inconvenient forum, and (iii) submits to
the non-exclusive jurisdiction of Delaware Courts in any suit, action or proceeding. Each of the parties agrees that a judgment in any suit, action or proceeding brought in a Delaware Court shall be conclusive and binding upon it and may be enforced
in any other courts to whose jurisdiction it is or may be subject, by suit upon such judgment. 
 (b) Each of the parties
agrees and acknowledges that any controversy that may arise under this Agreement is likely to involve complicated and difficult issues, and therefore each such party hereby irrevocably and unconditionally waives any right such party may have to a
trial by jury in respect of any litigation directly or indirectly arising out of or relating to this Agreement, or the breach, termination or validity of this Agreement. 
  

	10.	Specific Performance. 

 The Stockholder acknowledges and
agrees that (i) the covenants, obligations and agreements of the Stockholder contained in this Agreement relate to special, unique and extraordinary matters, (ii) the Company and Shield are and will be relying on such covenants in
connection with entering into the Merger Agreement and the performance of their obligations under the Merger Agreement, and (iii) a violation of any of the terms of such covenants, obligations or agreements will cause the Company and Shield
irreparable injury for which adequate remedies are not 

  

 6 

 
available at law. Therefore, such Stockholder agrees that the Company and Shield shall be entitled to seek an injunction, restraining order or such other
equitable relief (without the requirement to post bond) as a court of competent jurisdiction may deem necessary or appropriate to restrain such Stockholder from committing any violation of such covenants, obligations or agreements. 
  

	11.	Amendment, Waivers, Etc. 

 Neither this Agreement nor any
term hereof may be amended or otherwise modified other than by an instrument in writing signed by the Company and the Stockholder. No provision of this Agreement may be waived, discharged or terminated other than by an instrument in writing signed
by the party against whom the enforcement of such waiver, discharge or termination is sought. 
  

	12.	Assignment; No Third Party Beneficiaries. 

 This Agreement
shall not be assignable or otherwise transferable by a party without the prior consent of the other parties, and any attempt to so assign or otherwise transfer this Agreement without such consent shall be void and of no effect. This Agreement shall
be binding upon the respective heirs, legal representatives and permitted transferees of the parties hereto. Nothing in this Agreement shall be construed as giving any Person, other than the parties hereto and their heirs, legal representatives and
permitted transferees, any right, remedy or claim under or in respect of this Agreement or any provision hereof. No failure or delay by any party in exercising any right, power or privilege under this Agreement shall operate as a waiver thereof nor
shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies provided herein shall be cumulative and not exclusive of any rights or
remedies provided by law. 
  

	13.	Notices. 

 All notices, consents, requests, instructions,
approvals and other communications provided for in this Agreement shall be in writing and shall be deemed validly given upon personal delivery or one day after being sent by overnight courier service or by telecopy (so long as for notices or other
communications sent by telecopy, the transmitting telecopy machine records electronic confirmation of the due transmission of the notice), at the following address or telecopy number, or at such other address or telecopy number as a party may
designate to the other parties by written notice: 
  

			
	If to the Stockholder, to:        	  	the address set forth under such Stockholder’s name on Schedule A hereto
		
	If to eMerge to:	  	David C. Warren
		  	eMerge Interactive, Inc.
		  	10305 102nd Terrace
		  	Sebastian, FL 32958
		  	Telephone: (772) 581-9700
		  	Facsimile: (772) 581-0204

  

 7 

			
	with a copy to:	  	Hunton & Williams, LLP
		  	951 East Byrd Street
		  	Richmond, VA 23219
		  	Attention: Melvin E. Tull III, Esq.
		  	Telephone: (804) 788-8200
		  	Facsimile: (804) 788-8218
		
	If to the Company:        	  	David E. Hallberg
		  	Prime BioSolutions, LLC
		  	11905 P Street, Suite 101
		  	Omaha, NE 68137
		  	Telephone: (402) 932-8940
		  	Facsimile: (402) 932-8946
		
	with a copy to:	  	Kutak Rock LLP
		  	1650 Farnam Street
		  	Omaha, NE 68102
		  	Attention: Joseph O. Kavan, Esq.
		  	Telephone: (402) 346-6000
		  	Facsimile: (402) 346-1148

  

	14.	Severability. 

 If any provision of this Agreement is held to
be invalid or unenforceable for any reason, it shall be adjusted rather than voided, if possible, in order to achieve the intent of the parties hereto to the maximum extent possible. In any event, the invalidity or unenforceability of any provision
of this Agreement in any jurisdiction shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of this Agreement, including that provision, in any other jurisdiction.

  

	15.	Integration. 

 This Agreement (together with the Merger
Agreement to the extent referenced herein), including Schedule A hereto, constitutes the full and entire understanding and agreement of the parties with respect to the subject matter hereof and thereof and supersedes any and all prior
understandings or agreements relating to the subject matter hereof and thereof. 
  

	16.	Section Headings. 

 The section headings of this Agreement
are for convenience of reference only and are not to be considered in construing this Agreement. 
  

	17.	Counterparts. 

 This Agreement may be executed in several
counterparts (including by facsimile), each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 
  

 8 

	18.	Capitalized Terms. 

 For purposes of this Agreement,
capitalized terms used and not defined herein shall have the respective meanings ascribed to them in the Merger Agreement. 
  

	19.	Definitions. 

 References in this Agreement (except as
specifically otherwise defined) to “affiliates” shall mean, as to any person, any other person which, directly or indirectly, controls, or is controlled by, or is under common control with, such person. As used in this definition,
“control” (including, with its correlative meanings, “controlled by” and “under common control with”) shall mean the possession, directly or indirectly, of the power to direct or cause the direction of management or
policies of a person, whether through the ownership of securities or partnership or other ownership interests, by contract or otherwise. References in the Agreement to “person” shall mean an individual, a corporation, a partnership, an
association, a trust or any other entity, group (as such term is used in Section 13 of the Securities Exchange Act of 1934, as amended) or organization, including, without limitation, a governmental body or authority. 
  

	20.	Expenses. 

 If any action at law or in equity is necessary to
enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 
  

	21.	Disclosure. 

 Each of the parties hereto and their affiliates
are hereby authorized to publish or disclose in any requisite report filed by any of them with the SEC, including, without limitation, a Schedule 13D, his/her identity and the nature of the commitments, arrangements and understandings under
this Agreement. 
 [Signature page follows] 
  

 9 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and
date first above written. 
  

			
	PRIME BIOSOLUTIONS, LLC
		
	By:	 	 /s/ David E. Hallberg

	Name:	 	David E. Hallberg
	Title:	 	Chairman & CEO
	
	EMERGE INTERACTIVE, INC.
		
	By:	 	 /s/ David C. Warren

	Name:	 	David C. Warren
	Title:	 	President & CEO
	
	THE BIEGERT FAMILY IRREVOCABLE TRUST
		
	By:	 	 /s/ Judith Ackland

	Name:	 	Judith Ackland
	Title:	 	Trustee

  

 10 

 EXHIBIT A 
 TO VOTING AGREEMENT 
 STOCKHOLDERS 
  

					
	 NAME AND ADDRESS
	  	NUMBER
OF
SHARES
		
	The Biegert Family Irrevocable Trust, dated June 11, 1998	  	723,912
	Address: P.O. Box 429, Geneva, NE 68361	  	
	Contact person:	  	Judy Ackland	  	
	Phone number:	  	(402) 759-4994	  	
	Fax number:	  	(402) 759-4995	  	
		
	Safeguard Scientifics (Delaware), Inc.	  	276,928
	 Address: 800 The Safeguard Building, 435 Devon Park Drive,
 Wayne, PA 19087
	  	
	Contact person:	  	Dee Blackburn	  	
	Phone number:	  	(610) 975-4943	  	
	Fax number:	  	(610) 254-4338	  	
		
	Safeguard Delaware, Inc.	  	224,710
	 Address: 800 The Safeguard Building, 435 Devon Park Drive,
 Wayne, PA 19087
	  	
	Contact person:	  	Dee Blackburn	  	
	Phone number:	  	(610) 975-4943	  	
	Fax number:	  	(610) 254-4338Form of Employment Agreement

 EXHIBIT 10.1 
 EMPLOYMENT AGREEMENT 
 Agreement dated October 16, 2006 (the “Effective Date”), by and between Indevus
Pharmaceuticals, Inc., a Delaware corporation having a place of business at 33 Hayden Avenue, Lexington, Massachusetts 02421 (the “Corporation”), and Thomas Forest Farb, an individual residing at
                                        
(the “Officer”). 
 WITNESSETH: 
 WHEREAS, the Corporation desires to employ the Officer as President and Chief Operating Officer, and the Officer desires to be employed by the Corporation as President and Chief Operating Officer all pursuant to the terms and conditions
hereinafter set forth: 
 NOW, THEREFORE, in consideration of the foregoing and the mutual promises and covenants herein contained, it is agreed as follows:

  

	1.	EMPLOYMENT: DUTIES 

  

	 	(a)	The Corporation engages and employs the Officer, and the Officer hereby accepts engagement and employment, as have responsibility as President and Chief Operating Officer of the
Corporation and performing all services and duties as the Board of Directors of the Corporation shall determine including providing general corporate leadership and strategic direction and the primary supervision of multiple functional areas of the
Corporation, including but not limited to Finance, Sales and Marketing, Business Development and Human Resources. In his capacity as President and Chief Operating Officer of the Corporation, and as an officer of the Corporation, the Officer shall
report directly to the Chief Executive Officer of the Corporation. 

  

	 	(b)	The Officer shall perform his duties hereunder from the Corporation’s executive offices in Massachusetts, provided, however, that the Officer acknowledges and agrees that the
performance by the Officer of his duties hereunder may require domestic and international travel by the Officer. 

  

	 	(c)	The Officer shall devote his best efforts and principal working time and attention to the proper discharge of his duties and responsibilities under this Agreement.

  

	2.	TERM 

 Subject to the provisions of Section 6
hereof, the Officer’s employment hereunder shall be for a term of one (1) year commencing on the Effective Date and continuing through the first anniversary of such date and shall automatically renew for periods of one (1) year
commencing at the second anniversary of the 

 
Effective Date unless either the Officer or the Corporation gives written notice to the other not less than sixty (60) days prior to the date of any
such anniversary of such party’s election not to extend the term of this Agreement. 
  

	3.	COMPENSATION 

  

	 	(a)	As compensation for the performance of his duties under this Agreement, the Officer shall be compensated as follows: 

  

	 	(i)	The Corporation shall pay the Officer an annual base salary (“Base Salary”) of Four hundred and twenty-five thousand dollars ($425,000), payable in accordance with the
usual payroll period of the Corporation. The Compensation Committee of the Board of Directors of the Corporation will review the Officer’s base salary on an annual basis. 

  

	 	(ii)	The Officer shall be entitled to participate in the FY 2007 Senior Executive Officer Bonus Plan and subsequent Senior Executive Bonus Plans with a target bonus potential of 55% of
base salary. 

  

	 	(iii)	The Officer shall be eligible to receive options to purchase shares of the Corporation’s common stock, $.001 par value (“Common Stock”), under the Corporation’s
2004 Equity Incentive Plan, as amended, or such other option plans as may be in effect at any time during the term of this Agreement, as may be granted from time to time by the Compensation Committee of the Board of Directors.

  

	 	(iv)	Specifically, the Officer shall receive options to purchase 600,000 shares of the Corporation’s common stock. The basis price for these options will be the closing price of the
stock on October 16, 2006, the date of the Indevus board of director’s special meeting resolving and authorizing the Officer’s hire. These options will vest at the rate of 25% after the end of one year of employment, then will vest
6.25% every quarter for the next three years. 

  

	 	(v)	The Officer shall participate in the Corporation’s Senior Executive Long-Term Incentive Plan which provides for periodic grants of restricted stock and performance shares. As
of the Effective Date, the Officer shall receive 50,000 restricted shares and 60,000 performance shares under the same terms and conditions subject to the same criteria for vesting as the other executive officers of the company approved by the Board
of Directors in 2006. 

 The Corporation shall withhold all applicable federal, state, and local taxes, social security, and
workers’ compensation contributions as such other amounts as may be required by law and any plans pursuant to which such compensation is generated or agreed upon by the parties, and as may be allowed, with respect to the compensation payable to
the Officer pursuant to Section 3(a) hereof. 
  

 2 

	 	(b)	The Corporation shall reimburse the Officer for all normal, usual, and necessary expenses incurred by the Officer in furtherance of the business and affairs of the Corporation,
including reasonable travel and entertainment, against receipt by the Corporation of appropriate vouchers or other proof of the Officer’s expenditures and otherwise in accordance with such Expense Reimbursement Policy as may from time to time
be adopted by the Board of Directors of the Corporation. 

  

	 	(c)	The Officer shall be, during the term of this Agreement, entitled to vacations of not less than four (4) weeks per annum. 

  

	 	(d)	The Corporation shall make available to the Officer and his dependents such medical, disability, life insurance, and such other health benefits as the Corporation makes available to
its senior officers and directors. The Company shall reimburse the Officer for premiums for $1,000,000 additional term life insurance during the period of the Officer’s employment. 

  

	4.	NON-SOLICITATION  

  

	 	(a)	During the term of this Agreement and for one (1) year thereafter, the Officer shall not, directly or indirectly, without the prior written consent of the Corporation, solicit
or induce any employee of the Corporation or any affiliate to the leave the employ of the Company or any affiliate or hire for any purpose any employee of the Corporation or any affiliate or any employee who has left the employment of the
Corporation or any affiliate within six (6) months of the termination of said employee’s employment with the Corporation. 

  

	 	(b)	During the term of the Agreement and for one (1) year thereafter, the Officer shall not, directly or indirectly, without the prior written consent of the Corporation:

  

	 	(i)	solicit or accept employment or be retained by any party who, at any time during the term of his Agreement, was a customer or supplier of the Corporation or any affiliate where his
position will be related to the business of the Corporation; or 

  

	 	(ii)	solicit or accept the business of any customer or supplier of the Corporation or any affiliate with respect to products similar to those supplied by the Corporation.

  

 3 

	 	(c)	In the event that the Officer breaches any provisions of this Section 4 or there is a threatened breach, then, in addition to any other rights which the Corporation may have,
the Corporation shall be entitled, without the posting of a bond or other security, to injunctive relief to enforce the restrictions contained herein. In the event that an actual proceeding is brought in equity to enforce the provisions of this
Section 4, the Officer shall not urge as a defense that there is an adequate remedy at law nor shall the Corporation be prevented from seeking any other remedies which may be available. 

  

	5.	CONFIDENTAL INFORMATION 

  

	 	(a)	The Officer agrees that during the course of his employment or at any time after termination, he will not disclose or make accessible to any other person, the Corporation’s
products, services, and technology, both current and under development, promotion and marketing programs, lists, trade secrets, litigation information, and other confidential and proprietary business information of the Corporation or any of its
clients. The Officer agrees: (i) not to use any such information for himself or others; and (ii) not to take any such material or reproductions thereof from the Corporation’s facilities at any time during his employment at the
Corporation, except as required in the Officer’s duties to the Corporation. The Officer agrees immediately to return such material and reproductions thereof in his possession to the Corporation upon request and in any event upon termination of
employment. 

  

	 	(b)	Except with prior written authorization by the Corporation, the Officer agrees not to disclose or publish any of the confidential, technical or business information or material of
the Corporation, its clients or any other party to whom the Corporation owes an obligation of confidence, at any time during or after his employment with the Corporation. 

  

	 	(c)	The Officer hereby assigns to the Corporation all right, title, and interest he may have or may acquire in all inventions (including patent rights) developed by the Officer during
the term of this Agreement (“Inventions”) and agrees that all Inventions shall be the sole property of the Corporation and its assigns, and the Corporation and its assigns shall be the sole owner of all patents, copyrights, and other
rights in connection therewith. The Officer further agrees to assist the Corporation in every proper way (but at the Corporation’s expense) to obtain and from time to time enforce patents, copyrights, or other rights on said Inventions in any
and all countries. 

  

 4 

	6.	TERMINATION 

  

	 	(a)	The term of this Agreement shall continue for the period set forth in Section 2 hereof unless sooner terminated upon the first to occur of the following events:

  

	 	(i)	The death of the Officer; 

  

	 	(ii)	Termination for just cause. Any of the following actions by the Officer shall constitute just cause: 

  

	 	(A)	Material breach by the Officer of Section 4 or Section 5 of this agreement; 

  

	 	(B)	Material breach by the Officer of any provision of this Agreement other than Section 4 or Section 5 or the willful or reckless failure by the Officer to perform his duties
hereunder which breach or failure is not cured by the Officer within fifteen (15) days of notice thereof from the Corporation; or 

  

	 	(C)	The commission by the Officer of any act of fraud or theft against the Corporation or any of its subsidiaries, or the conviction of the Officer of any criminal act.

  

	 	(iii)	Termination by the Officer for just cause. Any of the following actions or omissions by the Corporation shall constitute just cause: 

  

	 	(A)	Material breach by the Corporation of any provision of this Agreement which is not cured by the Corporation within fifteen (15) days of notice thereof from the Officer;

  

	 	(B)	Any action by the Corporation to intentionally harm the Officer; or 

  

	 	(C)	A Change in Control of the Corporation (as defined below), unless the Officer is offered and, in his sole discretion, accepts either (1) a comparable executive position of the
acquirer or the division of the acquirer which assumes the business of the corporation of the Corporation after the Change in Control or (2) compensation comparable to that provided to the Officer under this agreement. 

 

	 	(iv)	Termination without just cause. 

  

	 	(b)	Upon termination pursuant to subparagraph (ii) of paragraph (a) above, the Officer, or his estate in the event of termination pursuant to subparagraph (i), shall be
entitled to receive the Base Salary accrued but unpaid as of the date of termination. 

  

 5 

	 	(c)	Upon termination pursuant to subparagraph (iii) of paragraph (a) above, the Officer shall be entitled to receive the Base Salary plus average bonuses paid to the Officer
since the Effective Date. At the discretion of the Corporation, such Base Salary may be paid in one lump sum or in monthly installments. In addition, the Corporation shall provide continuation of health benefits for twelve (12) months to the
extent authorized by and consistent with 29 U.S.C. § 1161 et seq. (commonly known as “COBRA”), with the cost of the regular premium for such benefit shared in the same relative proportion by the Corporation and the Officer as in
effect on the date of the termination. Notwithstanding the foregoing, nothing in this Section 6(c) shall be construed to affect the Officer’s right to receive COBRA continuation entirely at the Officer’s own cost to the extent that
the Officer may continue to be entitled to COBRA continuation after the Officer’s right to cost sharing under this Section 6(c) ceases. 

  

	 	(d)	Upon termination pursuant to subparagraph (iv) of paragraph (a) above, or if the Corporation does not renew this Agreement, the Corporation will pay to the Officer twelve
(12) months of Base Salary plus average bonuses. At the discretion of the Corporation, such base salary may be paid in one lump sum or in monthly installments. This payment, however, shall be reduced by the salary and bonus compensation from
other employment received by the Officer during the twelve (12) months following termination of the Agreement. In addition, the Corporation shall provide continuation of health benefits for twelve (12) months to the extent authorized by
and consistent with 29 U.S.C. § 1161 et seq. (commonly known as “COBRA”), with the cost of the regular premium for such benefit shared in the same relative proportion by the Corporation and the Officer as in effect on the date of the
termination. 

  

	 	(e)	For purposes of this Agreement, a “Change in Control of the Corporation” shall be deemed to have occurred if any “person” (as such term is used in
Section 13(d) and 14(d) of the Securities Exchange Act of 1934 (the “Exchange Act”)), becomes, after the date of this Agreement the “beneficial owner” (as defined in Rule 13(d)-3 under the Exchange Act), directly or
indirectly, of securities of the Corporation representing 50% or more of the combined voting power of the Corporation’s then outstanding securities. 

  

	 	(f)	 It is the intention of the Corporation and the CEO that no portion of the payment made under Section 6(c) hereof (the “Termination Payment”) be
deemed to be an excess parachute payment as defined in Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”). In the 

  

 6 

	 	 
event that in the opinion of the Corporation’s independent public accountants, all or any portion of the Termination Payment may be an excess parachute
payment, the Termination Payment hereunder shall be reduced or eliminated as specified by the CEO in writing delivered to the Corporation within 30 days of his receipt of such opinion or, if the CEO fails to so notify the Corporation, then as the
Corporation shall reasonably determine, so that there will be no excess parachute payment. 

  

	 	(g)	Cooperation: Pending Litigation 

  

	 	(i)	Upon request of the Company, in connection with any suit, action, proceeding, arbitration, or litigation involving the Corporation (a “Litigation”), which Litigation is
directly or indirectly the result of an event, fact, or occurrence existing, in whole or in part, prior to the Termination Date, the Officer agrees to, at the expense of the Corporation, in connection with any such Litigation”

  

	 	(A)	attend depositions, meetings, conferences, or other scheduled proceedings related to the Litigation with a designated Officer of the Corporation; 

  

	 	(B)	provide a written outline of any actions taken by the Officer on behalf of the Corporation, or any information know to the Officer; and 

  

	 	(C)	otherwise cooperate with the Corporation, counsel to the Corporation, and with other entities whom the Corporation shall reasonably request. 

  

	 	(ii)	Unless the Officer and the Corporation agree otherwise, the Officer shall not be required to engage or participate in any of the activities described in Section 6(g) of this
Agreement for more than three (3) consecutive business days at a time, or more than six (6) business days per ninety (90) day period. 

  

	7.	NOTICES 

 Any notice or other communication under
this agreement shall be in writing and shall be deemed to have been given: when delivered personally against receipt thereof; one (1) day after being sent by Federal Express or similar overnight delivery; or three (3) days after being
mailed registered or certified mail, postage prepaid, return receipt requested, to either party at the address set forth above, or to such other address as such party shall give by notice hereunder to the other party. 
  

 7 

	8.	INDEMNIFICATION 

 The Corporation will enter into an
indemnification agreement with the Officer substantially identical to that entered into with its other executive officers, in the form attached as Exhibit A hereto. 
  

	9.	SEVERABILITY OF PROVISIONS 

 If any provision of
this Agreement shall be declared by a court of competent jurisdiction to be invalid, illegal, or incapable of being enforced in whole or in part, such provision shall be interpreted so as to remain enforceable to the maximum extent permissible
consistent with applicable law and the remaining conditions and provisions or portions thereof shall nevertheless remain in full force and effect and enforceable to the extent they are valid, legal, and enforceable, and no provision shall be deemed
dependent upon any other covenant or provision unless so expressed herein. 
  

	10.	ENTIRE AGREEMENT: MODIFICATION 

 This Agreement
contains the entire agreement of the parties relating to the subject matter hereof, and the parties hereto have made no agreements, representations, or warranties relating to the subject matter of this Agreement which are not set forth herein. No
modification of this agreement shall be valid unless made in writing and signed by the parties hereto. 
  

	11.	BINDING EFFECT 

 The rights, benefits, duties, and
obligations under this Agreement shall inure to, and be binding upon, the Corporation, its successors and assigns, and upon the Officer and his legal representatives. This Agreement constitutes a personal service agreement, and the performance of
the Officer’s obligation hereunder may not be transferred or assigned by the Officer. 
  

	12.	NON-WAIVER 

 The failure of either party to insist
upon the strict performance of the terms, conditions, and provisions of this Agreement shall not be construed as a waiver or relinquishment of future compliance therewith, and said terms, conditions, and provisions shall remain in full force and
effect. No waiver of any term or condition of this Agreement on the part of either party shall be effective for any purpose whatsoever unless such waiver is in writing and signed by such party. 
  

	13.	GOVERNING LAW 

 This Agreement shall be governed by,
and construed and interpreted in accordance with, the laws of the Commonwealth of Massachusetts without regard to principles of conflicts of laws. 
  

 8 

	14.	MISCELLANEOUS 

 Within three business days of
employment, you will be required to present proof of eligibility to work in the United States in accordance with the Immigration Reform and Control Act. 
 The Employee Handbook documents the policies and procedures of Indevus and outlines the current benefit programs. The Officer is expected to be familiar with the policies and procedures of the Company and adhere to
them. Currently, employee benefits provided are group major medical, dental, life and disability insurances, and a 401(k) retirement savings program.
 The Corporation will conduct a background check. Enclosed please find a Consent and Disclosure Form authorizing the Corporation to begin the check. Within two weeks of beginning employment, the Officer will
be required to undergo a pre- employment drug screening at the Mount Auburn Hospital Occupational Health Service. A form and instructions for scheduling the drug screening are included with this letter. The results of the background check
and drug screening are kept confidential.
 The Officer understands that this offer of employment is contingent upon our completing reference
checking and my successful completion of the pre- employment screening process which may include a background, credential, educational, reference, credit, motor vehicle, criminal record check, and other checks, and the Officer hereby consents to the
same. 
 The heading of the paragraphs are inserted for convenience and shall not effect the interpretation of this Agreement on the day and
year first above written. 
  

			
	Indevus Pharmaceuticals, Inc.
		
	By:	 	  

		 	Glenn L. Cooper, M.D.
		 	Chairman, President, and Chief Executive Officer
		
		 	  

		 	Thomas Forest Farb

  

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}]]